Skip to main content
Top
Published in: Journal of Neurology 12/2009

Open Access 01-12-2009 | Original Communication

C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death

Authors: H. M. den Hertog, J. A. van Rossum, H. B. van der Worp, H. M. A. van Gemert, R. de Jonge, P. J. Koudstaal, D. W. J. Dippel, the PAIS investigators

Published in: Journal of Neurology | Issue 12/2009

Login to get access

Abstract

Acute ischemic stroke may trigger an inflammatory response that leads to increased levels of C-reactive protein (CRP). High levels of CRP may be associated with poor outcome because they reflect either an inflammatory reaction or tissue damage. We evaluated the prognostic value of CRP within 12 h of onset of ischemic stroke. Levels of CRP were routinely obtained within 12 h of symptom onset in 561 patients with ischemic stroke. CRP values were dichotomized as <7 or ≥7 mg/L. The full range of CRP values was used to detect a possible level-risk relationship. We studied the relation between CRP values and poor outcome (modified Rankin Scale score >2) or death at 3 months. A multiple logistic regression model was applied to adjust for age, sex, NIHSS score, current cigarette smoking, diabetes mellitus, hypertension, statin use, and stroke subtype. After adjustment for potential confounders, patients with CRP levels ≥7 mg/L had a significantly increased risk of poor outcome (adjusted OR 1.6, 95% CI 1.1–2.4) or death (adjusted OR 1.7, 95% CI 1.0–2.9) at 3 months. In addition, the risk of poor outcome or death at 3 months increased with higher levels of CRP. CRP within 12 h of ischemic stroke is an independent prognostic factor of poor outcome at 3 months.
Appendix
Available only for authorised users
Literature
1.
go back to reference Adams HP, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMed Adams HP, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41PubMed
2.
go back to reference Albert MA, Danielson E, Rifai N et al (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286:64–70CrossRefPubMed Albert MA, Danielson E, Rifai N et al (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286:64–70CrossRefPubMed
3.
go back to reference Aslanyan S, Weir CJ, Diener HC et al (2004) Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol 11:49–53CrossRefPubMed Aslanyan S, Weir CJ, Diener HC et al (2004) Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol 11:49–53CrossRefPubMed
4.
go back to reference Barone FC, Feuerstein GZ (1999) Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19:819–834CrossRefPubMed Barone FC, Feuerstein GZ (1999) Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19:819–834CrossRefPubMed
5.
go back to reference Brott T, Adams HP, Olinger CP et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870PubMed Brott T, Adams HP, Olinger CP et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870PubMed
6.
go back to reference Christensen H, Boysen G (2004) C-reactive protein and white blood cell count increases in the first 24 h after acute stroke. Cerebrovasc Dis 18:214–219CrossRefPubMed Christensen H, Boysen G (2004) C-reactive protein and white blood cell count increases in the first 24 h after acute stroke. Cerebrovasc Dis 18:214–219CrossRefPubMed
7.
go back to reference den Hertog HM, van der Worp HB, van Gemert HM et al (2008) Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]. BMC Cardiovasc Disord 8:29CrossRefPubMed den Hertog HM, van der Worp HB, van Gemert HM et al (2008) Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]. BMC Cardiovasc Disord 8:29CrossRefPubMed
8.
go back to reference Di Napoli M, Papa F, Bocola V (2001) C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32:917–924PubMed Di Napoli M, Papa F, Bocola V (2001) C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32:917–924PubMed
9.
go back to reference Di Napoli M, Papa F, Bocola V (2001) Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32:133–138PubMed Di Napoli M, Papa F, Bocola V (2001) Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32:133–138PubMed
10.
go back to reference Di Napoli M, Schwaninger M, Cappelli R et al (2005) Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36:1316–1329CrossRefPubMed Di Napoli M, Schwaninger M, Cappelli R et al (2005) Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36:1316–1329CrossRefPubMed
11.
go back to reference Emsley HC, Hopkins SJ (2008) Acute ischemic stroke and infection: recent and emerging concepts. Lancet Neurol 7:341–353CrossRefPubMed Emsley HC, Hopkins SJ (2008) Acute ischemic stroke and infection: recent and emerging concepts. Lancet Neurol 7:341–353CrossRefPubMed
12.
go back to reference Emsley HC, Smith CJ, Gavin CM et al (2003) An early and sustained peripheral inflammatory response in acute ischemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 139:93–101CrossRefPubMed Emsley HC, Smith CJ, Gavin CM et al (2003) An early and sustained peripheral inflammatory response in acute ischemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 139:93–101CrossRefPubMed
13.
go back to reference Gill R, Kemp JA, Sabin C, Pepys MB (2004) Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 24:1214–1218CrossRefPubMed Gill R, Kemp JA, Sabin C, Pepys MB (2004) Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 24:1214–1218CrossRefPubMed
14.
go back to reference Griselli M, Herbert J, Hutchinson WL et al (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733–1740CrossRefPubMed Griselli M, Herbert J, Hutchinson WL et al (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733–1740CrossRefPubMed
15.
go back to reference Kocer A, Canbulat C, Gozke E et al (2005) C-reactive protein is an indicator for fatal outcomes in first-time stroke patients. Med Sci Monit 11:CR540–CR544PubMed Kocer A, Canbulat C, Gozke E et al (2005) C-reactive protein is an indicator for fatal outcomes in first-time stroke patients. Med Sci Monit 11:CR540–CR544PubMed
16.
go back to reference Kushner I, Agrawal A (2007) CRP can play both pro-inflammatory and anti-inflammatory roles. Mol Immunol 44:670–671CrossRefPubMed Kushner I, Agrawal A (2007) CRP can play both pro-inflammatory and anti-inflammatory roles. Mol Immunol 44:670–671CrossRefPubMed
17.
go back to reference Ladenvall C, Jood K, Blomstrand C et al (2006) Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 37:2018–2023CrossRefPubMed Ladenvall C, Jood K, Blomstrand C et al (2006) Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 37:2018–2023CrossRefPubMed
18.
go back to reference Masotti L, Ceccarelli E, Forconi S et al (2005) Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med 258:145–152CrossRefPubMed Masotti L, Ceccarelli E, Forconi S et al (2005) Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med 258:145–152CrossRefPubMed
19.
go back to reference McColl BW, Allan SM, Rothwell NJ (2007) Systemic inflammation and stroke: aetiology, pathology and targets for therapy. Biochem Soc Trans 35:1163–1165CrossRefPubMed McColl BW, Allan SM, Rothwell NJ (2007) Systemic inflammation and stroke: aetiology, pathology and targets for therapy. Biochem Soc Trans 35:1163–1165CrossRefPubMed
20.
go back to reference Montaner J, Fernandez-Cadenas I, Molina CA et al (2006) Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37:1205–1210CrossRefPubMed Montaner J, Fernandez-Cadenas I, Molina CA et al (2006) Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37:1205–1210CrossRefPubMed
21.
go back to reference Muir KW, Weir CJ, Alwan W et al (1999) C-reactive protein and outcome after ischemic stroke. Stroke 30:981–985PubMed Muir KW, Weir CJ, Alwan W et al (1999) C-reactive protein and outcome after ischemic stroke. Stroke 30:981–985PubMed
22.
go back to reference Pepys MB, Hirschfield GM, Tennent GA et al (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217–1221CrossRefPubMed Pepys MB, Hirschfield GM, Tennent GA et al (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217–1221CrossRefPubMed
23.
go back to reference Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMed Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207CrossRefPubMed
24.
go back to reference Ridker PM, Rifai N, Pfeffer MA et al (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235PubMed Ridker PM, Rifai N, Pfeffer MA et al (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235PubMed
25.
go back to reference Smith CJ, Emsley HC, Gavin CM et al (2004) Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 4:2CrossRefPubMed Smith CJ, Emsley HC, Gavin CM et al (2004) Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 4:2CrossRefPubMed
26.
go back to reference Smith CJ, Emsley HC, Vail A et al (2006) Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 251:77–81CrossRefPubMed Smith CJ, Emsley HC, Vail A et al (2006) Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 251:77–81CrossRefPubMed
27.
go back to reference Topakian R, Strasak AM, Nussbaumer K et al (2008) Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol 255:1190–1196CrossRefPubMed Topakian R, Strasak AM, Nussbaumer K et al (2008) Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol 255:1190–1196CrossRefPubMed
28.
go back to reference van Breda EJ, van der Worp HB, van Gemert HM et al (2005) PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial [ISRCTN 74418480]. BMC Cardiovasc Disord 5:24CrossRefPubMed van Breda EJ, van der Worp HB, van Gemert HM et al (2005) PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial [ISRCTN 74418480]. BMC Cardiovasc Disord 5:24CrossRefPubMed
29.
go back to reference van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607PubMed van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607PubMed
30.
go back to reference Winbeck K, Poppert H, Etgen T et al (2002) Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33:2459–2464CrossRefPubMed Winbeck K, Poppert H, Etgen T et al (2002) Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33:2459–2464CrossRefPubMed
Metadata
Title
C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death
Authors
H. M. den Hertog
J. A. van Rossum
H. B. van der Worp
H. M. A. van Gemert
R. de Jonge
P. J. Koudstaal
D. W. J. Dippel
the PAIS investigators
Publication date
01-12-2009
Publisher
D. Steinkopff-Verlag
Published in
Journal of Neurology / Issue 12/2009
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-009-5228-x

Other articles of this Issue 12/2009

Journal of Neurology 12/2009 Go to the issue